Pathstone Holdings LLC Purchases 7,412 Shares of Encompass Health Co. (NYSE:EHC)

Pathstone Holdings LLC increased its holdings in shares of Encompass Health Co. (NYSE:EHC) by 54.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,022 shares of the company’s stock after purchasing an additional 7,412 shares during the quarter. Pathstone Holdings LLC’s holdings in Encompass Health were worth $2,032,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in EHC. CIBC Asset Management Inc grew its position in Encompass Health by 3.5% in the third quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock valued at $286,000 after purchasing an additional 100 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Encompass Health by 1.3% in the second quarter. Commonwealth Equity Services LLC now owns 9,845 shares of the company’s stock valued at $845,000 after acquiring an additional 123 shares in the last quarter. V Square Quantitative Management LLC increased its stake in Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after acquiring an additional 140 shares during the period. O Shaughnessy Asset Management LLC raised its position in shares of Encompass Health by 3.9% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,246 shares of the company’s stock valued at $351,000 after buying an additional 160 shares in the last quarter. Finally, Verdence Capital Advisors LLC lifted its position in shares of Encompass Health by 4.6% during the 3rd quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company’s stock worth $355,000 after buying an additional 160 shares during the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Up 1.7 %

EHC opened at $103.77 on Wednesday. Encompass Health Co. has a fifty-two week low of $63.78 and a fifty-two week high of $104.55. The firm has a market capitalization of $10.45 billion, a PE ratio of 25.07, a P/E/G ratio of 1.34 and a beta of 0.88. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The company’s 50-day moving average is $97.28 and its 200 day moving average is $90.99.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.94 by $0.09. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.86 earnings per share. As a group, research analysts predict that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 annualized dividend and a dividend yield of 0.66%. Encompass Health’s payout ratio is 16.43%.

Wall Street Analyst Weigh In

EHC has been the subject of a number of research reports. Truist Financial reiterated a “buy” rating and issued a $116.00 price target (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Barclays increased their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. UBS Group boosted their price target on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. KeyCorp raised their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Finally, Royal Bank of Canada increased their target price on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.